Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in PLoS One Retrieve available abstracts of 106 articles: HTML format

Single Articles

January 2025
1. CELDIR MG, Wehby G, Prakash S, Tanaka T, et al
   July effect in hospitalized cirrhosis patients: A US nationwide study using difference-in-differences analysis.
   PLoS One. 2025;20:e0316445.
   PubMed     Abstract available
   
   
   
2. KIM M, Jun BG, Shin HS, Yi JJ, et al
   Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: A population-based prospective cohort study.
   PLoS One. 2025;20:e0316175.
   PubMed     Abstract available
   
   
   
3. TOY M, Hutton D, Conners EE, Pham H, et al
   Cost-effectiveness of monitoring and liver cancer surveillance among patients with inactive chronic hepatitis B.
   PLoS One. 2025;20:e0313898.
   PubMed     Abstract available
   
   
   
4. DOFFOEL M, Chaffraix F, Chahard A, Gras D, et al
   Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks.
   PLoS One. 2025;20:e0316158.
   PubMed     Abstract available
   
   
   
5. YU L, Yu P, Cao Y, Cao W, et al
   Mechanism of Radix Bupleuri and Hedysarum Multijugum Maxim drug pairs on liver fibrosis based on network pharmacology, bioinformatics and molecular dynamics simulation.
   PLoS One. 2025;20:e0318336.
   PubMed     Abstract available
   
   
   
6. STRAJHAR P, Berzigotti A, Nilius H, Nagler M, et al
   Estimating the prevalence of adults at risk for advanced hepatic fibrosis using FIB-4 in a Swiss tertiary care hospital.
   PLoS One. 2025;20:e0317629.
   PubMed     Abstract available
   
   
   
7. SCHLEICHER EM, Tuchscher J, Weber M, Galle PR, et al
   Impact of type 2 diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis.
   PLoS One. 2025;20:e0316490.
   PubMed     Abstract available
   
   
   
8. MOHAMMADI M, Hasjim BJ, Balbale SN, Polineni P, et al
   Disease trajectory and competing risks of patients with cirrhosis in the US.
   PLoS One. 2025;20:e0313152.
   PubMed     Abstract available
   
   
   
9. CHO EH, Kim JA, Park MS, Kwon MJ, et al
   Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease.
   PLoS One. 2025;20:e0318847.
   PubMed     Abstract available
   
   
   
10. SKLADANY L, Zilincanova D, Zilincan M, Okapec S, et al
    Hepatic venous pressure gradient in patients with (compensated and decompensated) advanced chronic liver disease - A comparison of metabolic dysfunction-associated steatotic liver disease with alcohol-associated liver disease: A retrospective view.
    PLoS One. 2025;20:e0317287.
    PubMed     Abstract available
    
    
    
11. TEWKESBURY DH, Scott JA, Bright-Thomas RJ, Liong S, et al
    Proof of concept pilot study to assess the utility of magnetic resonance extra-cellular volume quantification to diagnose advanced liver disease in people with Cystic Fibrosis.
    PLoS One. 2025;20:e0318085.
    PubMed     Abstract available
    
    
    
12. 
    Expression of Concern: Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
    PLoS One. 2025;20:e0320610.
    PubMed    
    
    
    
13. GUO W, Weng T, Song Y
    Association of serum iron status with MASLD and liver fibrosis.
    PLoS One. 2025;20:e0319057.
    PubMed     Abstract available
    
    
    
14. LI Z, Guo H, He H, Wang S, et al
    The relationship between smoking cessation history and significant liver fibrosis among the population with metabolic dysfunction-associated steatotic liver disease in the United States.
    PLoS One. 2025;20:e0320573.
    PubMed     Abstract available
    
    
    
15. CELDIR MG, Wehby G, Prakash S, Tanaka T, et al
    Correction: July effect in hospitalized cirrhosis patients: A US nationwide study using difference-in-differences analysis.
    PLoS One. 2025;20:e0323476.
    PubMed     Abstract available
    
    
    
16. FICHTNER UA, Maun A, Farin-Glattacker E
    Predictors for psychosocial consequences of screening for liver diseases: A data-driven approach.
    PLoS One. 2025;20:e0319488.
    PubMed     Abstract available
    
    
    
17. ELIAS TP, Shewaye AB, Fisseha H, Nur AM, et al
    Predictors of in-hospital mortality among cirrhotic patients in Ethiopia: A multicenter retrospective study.
    PLoS One. 2025;20:e0322532.
    PubMed     Abstract available
    
    
    
18. HJORTH M, Forsberg A
    Predictive factors for limited health literacy among persons with cirrhosis: A Swedish explorative cross-sectional study.
    PLoS One. 2025;20:e0321780.
    PubMed     Abstract available
    
    
    
19. ZHAO K, Hu HT, Li HL, Cheng HT, et al
    Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.
    PLoS One. 2025;20:e0323829.
    PubMed     Abstract available
    
    
    
20. LU H, Mao Z, Zheng M, Zhang M, et al
    Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning.
    PLoS One. 2025;20:e0324972.
    PubMed     Abstract available
    
    
    
21. LEE CW, Kang ES, Jeong S, Han HW, et al
    Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study.
    PLoS One. 2025;20:e0323880.
    PubMed     Abstract available
    
    
    
22. YOO HW, Yang CJ, Yoo JJ, Chang Y, et al
    Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease.
    PLoS One. 2025;20:e0322102.
    PubMed     Abstract available
    
    
    
23. GRANDT J, Johansen CD, Jensen AH, Werge MP, et al
    The hepatic transcriptome is differentially regulated by a standardized meal in healthy individuals compared to patients with fatty liver disease.
    PLoS One. 2025;20:e0307345.
    PubMed     Abstract available
    
    
    
24. BUTTLER L, Tiede A, Griemsmann M, Rieland H, et al
    Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.
    PLoS One. 2025;20:e0325673.
    PubMed     Abstract available
    
    
    
25. HUANG S, Hu W, Fang T
    The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.
    PLoS One. 2025;20:e0325961.
    PubMed     Abstract available
    
    
    
26. THEEL W, Brouwer WP, van Rossum E, Apers J, et al
    Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.
    PLoS One. 2025;20:e0324813.
    PubMed     Abstract available
    
    
    
27. ALBHAISI S, Robinson A, Alsaadawi R, Sabo RT, et al
    Liver-related outcomes in patients with cirrhosis: The value of clinical and laboratory data and noninvasive tests.
    PLoS One. 2025;20:e0326702.
    PubMed     Abstract available
    
    
    
28. AHN J, Kim S, Jeong JY, Heo S, et al
    Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD.
    PLoS One. 2025;20:e0328207.
    PubMed     Abstract available
    
    
    
29. DUO H, You J, Du S, Yu M, et al
    Liver cirrhosis in 2021: Global Burden of Disease study.
    PLoS One. 2025;20:e0328493.
    PubMed     Abstract available
    
    
    
30. AHMED RF, Elgamal AM, El-Nashar HAS, Mowaad NA, et al
    Phenolic-rich extracts of Teucrium oliverianum confer protection against thioacetamide-induced liver fibrosis in rats: Insights from metabolomics, biochemical and histopathological analysis.
    PLoS One. 2025;20:e0330595.
    PubMed     Abstract available
    
    
    
31. XU C, Wang G, Zhang M, Lv L, et al
    Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.
    PLoS One. 2025;20:e0332490.
    PubMed     Abstract available
    
    
    
32. CHAI L, Zhou Y, Zhou N, Xiao Y, et al
    Machine learning-based prediction model for 28-day mortality in acute kidney injury patients with liver cirrhosis: A MIMIC-IV database analysis.
    PLoS One. 2025;20:e0328662.
    PubMed     Abstract available
    
    
    
33. MULLER-KUHNLE J, Schanz M, Schricker S, Benignus C, et al
    Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models.
    PLoS One. 2025;20:e0332840.
    PubMed     Abstract available
    
    
    
34. SUTTAWONG N, Witayavanitkul N, Chayanupatkul M, Wanpiyarat N, et al
    Gardenia jasminoides fruit extract ameliorates non-alcoholic steatohepatitis with fibrosis by modulating inflammatory and fibrogenic pathways.
    PLoS One. 2025;20:e0333800.
    PubMed     Abstract available
    
    
    
35. HOLINKA M, Frankova S, Adamcova Selcanova S, Skladany L, et al
    Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression.
    PLoS One. 2025;20:e0333051.
    PubMed     Abstract available
    
    
    
36. SAN MARTIN VALENZUELA C, Gallego JJ, Urios A, Correa-Ghisays P, et al
    Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis.
    PLoS One. 2025;20:e0333029.
    PubMed     Abstract available
    
    
    
37. MIGNOT V, Fabre O, Legrand R, Bailly S, et al
    FIB-4: A screening tool for advanced liver fibrosis in a cohort of subjects participating in a primary care weight-loss program.
    PLoS One. 2025;20:e0333490.
    PubMed     Abstract available
    
    
    January 2024
38. KOGISO T, Takayanagi K, Ishizuka T, Otsuka M, et al
    Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
    PLoS One. 2024;19:e0296375.
    PubMed     Abstract available
    
    
    
39. QIANG B, Xu Q, Pan Y, Wang J, et al
    Shear wave elastography: A noninvasive approach for assessing acute kidney injury in critically ill patients.
    PLoS One. 2024;19:e0296411.
    PubMed     Abstract available
    
    
    
40. SATO T, Oishi K
    Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
    PLoS One. 2024;19:e0296950.
    PubMed     Abstract available
    
    
    
41. LIU Z, Shao Y, Duan X
    Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298225.
    PubMed     Abstract available
    
    
    
42. LADNER DP, Gmeiner M, Hasjim BJ, Mazumder N, et al
    Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
    PLoS One. 2024;19:e0298887.
    PubMed     Abstract available
    
    
    
43. LI YS, Xia YG, Liu YL, Jiang WR, et al
    Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0297883.
    PubMed     Abstract available
    
    
    
44. BAGER P, Bossen L, Gantzel R, Gronbaek H, et al
    High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial.
    PLoS One. 2024;19:e0301354.
    PubMed     Abstract available
    
    
    
45. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
    Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
    PLoS One. 2024;19:e0301198.
    PubMed     Abstract available
    
    
    
46. RAN S, Song L, Yang H, Yu J, et al
    Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-kappaB-mediated hepatocyte pyroptosis.
    PLoS One. 2024;19:e0301133.
    PubMed     Abstract available
    
    
    
47. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    PubMed     Abstract available
    
    
    
48. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    PubMed     Abstract available
    
    
    
49. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    PubMed     Abstract available
    
    
    
50. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
    Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
    PLoS One. 2024;19:e0294695.
    PubMed     Abstract available
    
    
    
51. PAN Z, Bayoumi A, Metwally M, George J, et al
    Exportin 4 DNA promoter methylation in liver fibrosis.
    PLoS One. 2024;19:e0302786.
    PubMed     Abstract available
    
    
    
52. TABACU L, Swami S, Ledbetter M, Siddiqui MS, et al
    Socioeconomic status and health disparities drive differences in accelerometer-derived physical activity in fatty liver disease and significant fibrosis.
    PLoS One. 2024;19:e0301774.
    PubMed     Abstract available
    
    
    
53. YUAN C, Li W, Liu J, Li J, et al
    Frailty and transplant-free survival of patients with liver cirrhosis: A meta-analysis.
    PLoS One. 2024;19:e0302836.
    PubMed     Abstract available
    
    
    
54. GALIERO R, Loffredo G, Simeon V, Caturano A, et al
    Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy.
    PLoS One. 2024;19:e0296495.
    PubMed     Abstract available
    
    
    
55. OSAWA Y, Kawai H, Nakashima K, Nakaseko Y, et al
    Sphingosine-1-phosphate promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.
    PLoS One. 2024;19:e0303296.
    PubMed     Abstract available
    
    
    
56. CHU YH, Pang BY, Yang M, Meng Q, et al
    The intervention of curcumin on rodent models of hepatic fibrosis: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0304176.
    PubMed     Abstract available
    
    
    
57. TARU MG, Tefas C, Neamti L, Minciuna I, et al
    FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
    PLoS One. 2024;19:e0303971.
    PubMed     Abstract available
    
    
    
58. PFISTERER N, Schwarz M, Schwarz C, Putre F, et al
    Statins, metformin, and RAS inhibitors did not reduce variceal bleeding risk and mortality in a large, real-life cohort of patients with cirrhosis.
    PLoS One. 2024;19:e0302811.
    PubMed     Abstract available
    
    
    
59. WANG F, Gan J, Li R, Yang R, et al
    Naringin from Ganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-beta-Smad signaling pathway.
    PLoS One. 2024;19:e0304185.
    PubMed     Abstract available
    
    
    
60. NAM DE, Park SJ, Omole S, Um E, et al
    Activated Gab1 drives hepatocyte proliferation and anti-apoptosis in liver fibrosis via potential involvement of the HGF/c-Met signaling axis.
    PLoS One. 2024;19:e0306345.
    PubMed     Abstract available
    
    
    
61. PAUKNER M, Ladner DP, Zhao L
    Dynamic risk prediction of survival in liver cirrhosis: A comparison of landmarking approaches.
    PLoS One. 2024;19:e0306328.
    PubMed     Abstract available
    
    
    
62. QUITETE FT, Teixeira AVS, Peixoto TC, Martins BC, et al
    Long-term exposure to polychlorinated biphenyl 126 induces liver fibrosis and upregulates miR-155 and miR-34a in C57BL/6 mice.
    PLoS One. 2024;19:e0308334.
    PubMed     Abstract available
    
    
    
63. DU PISANIE JL, Ramakrishnan V, Patel V, Commander C, et al
    MRI paraspinous skeletal muscle enhancement: A potential imaging biomarker for assessing clinical liver cirrhosis severity.
    PLoS One. 2024;19:e0308520.
    PubMed     Abstract available
    
    
    
64. KATSUMI T, Sato H, Murakami R, Hanatani T, et al
    Identification of microbial antigens in liver tissues involved in the pathogenesis of primary biliary cholangitis using 16S rRNA metagenome analysis.
    PLoS One. 2024;19:e0308912.
    PubMed     Abstract available
    
    
    
65. WOOLLEY JJ, Fishman J, Parrinello CM, O'Connell T, et al
    Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020.
    PLoS One. 2024;19:e0309617.
    PubMed     Abstract available
    
    
    
66. PAIK JM, Shah D, Eberly K, Golabi P, et al
    Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States' National Vital Statistics System.
    PLoS One. 2024;19:e0289202.
    PubMed     Abstract available
    
    
    
67. SEPEHRINEZHAD A, Moghaddam NG, Shayan N, Sahab Negah S, et al
    Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307899.
    PubMed     Abstract available
    
    
    
68. XUE H, Liu Y, Liu Y, Li H, et al
    Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.
    PLoS One. 2024;19:e0310017.
    PubMed     Abstract available
    
    
    
69. LU Y, Mohammad NS, Lee J, Aranyos AM, et al
    Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model.
    PLoS One. 2024;19:e0310524.
    PubMed     Abstract available
    
    
    
70. FORLANO R, Stanic T, Jayawardana S, Mullish BH, et al
    Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community.
    PLoS One. 2024;19:e0307500.
    PubMed     Abstract available
    
    
    
71. OHKAWA K, Nakabori T, Mukai K, Kozumi K, et al
    Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
    PLoS One. 2024;19:e0311930.
    PubMed     Abstract available
    
    
    
72. PILLING D, Martinez TC, Gomer RH
    Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor.
    PLoS One. 2024;19:e0308060.
    PubMed     Abstract available
    
    
    
73. WEJNARUEMARN S, Suksawatamnuay S, Vanichanan J, Komolmit P, et al
    Association between serum endocan levels and organ failure in hospitalized patients with cirrhosis.
    PLoS One. 2024;19:e0315619.
    PubMed     Abstract available
    
    
    
74. GUO W, Weng T, Song Y
    Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study.
    PLoS One. 2024;19:e0314780.
    PubMed     Abstract available
    
    
    January 2023
75. THRIFT AP, Kanwal F, Liu Y, Khaderi S, et al
    Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score.
    PLoS One. 2023;18:e0282309.
    PubMed     Abstract available
    
    
    
76. ZHOU T, Wei H, Wang J
    Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.
    PLoS One. 2023;18:e0279431.
    PubMed     Abstract available
    
    
    
77. VOROS K, Markus B, Atzel K, Szalay F, et al
    Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.
    PLoS One. 2023;18:e0282801.
    PubMed     Abstract available
    
    
    
78. GE C, Ma C, Cui J, Dong X, et al
    Rapamycin suppresses inflammation and increases the interaction between p65 and IkappaBalpha in rapamycin-induced fatty livers.
    PLoS One. 2023;18:e0281888.
    PubMed     Abstract available
    
    
    
79. HJORTH M, Svanberg A, Sjoberg D, Rorsman F, et al
    Feeling safe or falling through the cracks-Patients' experiences of healthcare in cirrhosis illness: A qualitative study.
    PLoS One. 2023;18:e0283611.
    PubMed     Abstract available
    
    
    
80. RIDDELL J, Hempenstall A, Nakata Y, Gregson S, et al
    The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management.
    PLoS One. 2023;18:e0284151.
    PubMed     Abstract available
    
    
    
81. YU L, Paski SC, Dodge J, Bambha K, et al
    Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    PLoS One. 2023;18:e0284739.
    PubMed     Abstract available
    
    
    
82. NIITSU Y, Komiya C, Takeuchi A, Hara K, et al
    Increased serum extracellular vesicle miR-144-3p and miR-486a-3p in a mouse model of adipose tissue regeneration promote hepatocyte proliferation by targeting Txnip.
    PLoS One. 2023;18:e0284989.
    PubMed     Abstract available
    
    
    
83. AWASTHI A, Katiyar H, Rungta S, Deep A, et al
    Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naive non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PLoS One. 2023;18:e0285725.
    PubMed     Abstract available
    
    
    
84. DU R, Tang XY, Yang C, Gao WH, et al
    Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    PLoS One. 2023;18:e0284859.
    PubMed     Abstract available
    
    
    
85. LI X, Lu Y, Liang X, Zhou X, et al
    A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    PLoS One. 2023;18:e0286257.
    PubMed     Abstract available
    
    
    
86. HU J, Xie C, Xu S, Pu Q, et al
    Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.
    PLoS One. 2023;18:e0286017.
    PubMed     Abstract available
    
    
    
87. HE S, Zhang Y, Tan C, Tan W, et al
    Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES.
    PLoS One. 2023;18:e0286688.
    PubMed     Abstract available
    
    
    
88. MITROVIC N, Sabanovic M, Vujovic A, Jovanovic J, et al
    Influence of chronic liver diseases on the course and outcome of COVID-19.
    PLoS One. 2023;18:e0288350.
    PubMed     Abstract available
    
    
    
89. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    PubMed     Abstract available
    
    
    
90. SUZUKI-KEMURIYAMA N, Abe A, Nakane S, Yuki M, et al
    Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    PLoS One. 2023;18:e0287657.
    PubMed     Abstract available
    
    
    
91. LIAO Z, Wang Z, Su C, Pei Y, et al
    Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0290164.
    PubMed     Abstract available
    
    
    
92. SCHWARZ M, Schwarz C, Burghart L, Pfisterer N, et al
    Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.
    PLoS One. 2023;18:e0290352.
    PubMed     Abstract available
    
    
    
93. SEO HY, Lee SH, Park JY, Han E, et al
    Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver.
    PLoS One. 2023;18:e0290532.
    PubMed     Abstract available
    
    
    
94. SCHMIDT U, Uluca B, Vokic I, Malik B, et al
    Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice.
    PLoS One. 2023;18:e0286256.
    PubMed     Abstract available
    
    
    
95. YOSHIDA Y, Atsukawa M, Kondo C, Kitamura M, et al
    A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.
    PLoS One. 2023;18:e0292019.
    PubMed     Abstract available
    
    
    
96. BEER S, Babel J, Martin N, Blank V, et al
    Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
    PLoS One. 2023;18:e0286882.
    PubMed     Abstract available
    
    
    
97. GNANAPANDITHAN K, Ghali MP
    Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey.
    PLoS One. 2023;18:e0293315.
    PubMed     Abstract available
    
    
    
98. PHAM HN, Pham L, Sato K
    Bioinformatic analysis identified novel candidate genes with the potentials for diagnostic blood testing of primary biliary cholangitis.
    PLoS One. 2023;18:e0292998.
    PubMed     Abstract available
    
    
    
99. CHACON C, Arteaga I, Martinez-Escude A, Ruiz Rojano I, et al
    Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol.
    PLoS One. 2023;18:e0286586.
    PubMed     Abstract available
    
    
    
100. NAGAKAWA K, Hidaka M, Hara T, Matsushima H, et al
     Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
     PLoS One. 2023;18:e0293593.
     PubMed     Abstract available
     
     
     
101. ANTWI MB, Dumitriu G, Simon-Santamaria J, Romano JS, et al
     Liver sinusoidal endothelial cells show reduced scavenger function and downregulation of Fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt/gt mouse model of slowly progressing liver fibrosis.
     PLoS One. 2023;18:e0293526.
     PubMed     Abstract available
     
     
     
102. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
     Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
     PLoS One. 2023;18:e0287465.
     PubMed     Abstract available
     
     
     
103. WANG B, Kaufmann B, Mogler C, Zhong S, et al
     Hepatocellular Brg1 promotes CCl4-induced liver inflammation, ECM accumulation and fibrosis in mice.
     PLoS One. 2023;18:e0294257.
     PubMed     Abstract available
     
     
     
104. MOUNIKA N, Yadav A, Kamboj P, Banerjee SK, et al
     Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
     PLoS One. 2023;18:e0295839.
     PubMed     Abstract available
     
     
     January 2021
105. YEN HH, Su PY, Huang SP, Wu L, et al
     Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
     PLoS One. 2021;16:e0252286.
     PubMed     Abstract available
     
     
     
106. CONGLY SE, Shaheen AA, Swain MG
     Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
     PLoS One. 2021;16:e0251741.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.